The rate of the composite end point of all-cause mortality , re-infarction , target vessel revascularization , stroke and/or heart failure was 6.4 % ( N = 15 ) in the epoetin alfa group and 9.6 % ( N = 24 ) in the control group ( p = 0.18 ) .
